Stockscreener 앱 받기
95.47
6.00%
-6.09
시간 외 거래:
95.40
-0.07
-0.07%
전일 마감가:
$101.56
열려 있는:
$97.13
하루 거래량:
27.72M
Relative Volume:
2.34
시가총액:
$165.90B
수익:
$44.33B
순이익/손실:
$6.50B
주가수익비율:
25.68
EPS:
3.717
순현금흐름:
$7.40B
1주 성능:
-7.06%
1개월 성능:
-13.17%
6개월 성능:
-25.20%
1년 성능:
-26.39%
1일 변동 폭
$93.92
$99.00
1주일 범위
$93.92
$102.77
52주 변동 폭
$93.92
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
95.47 | 176.48B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
338.38 | 130.69B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.65 | 111.83B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
63.42 | 96.02B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
79.05 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Flu Season Fades, Abbott Stumbles: Is the 54-Year Dividend King Still Worth the Crown? - NAI500
New cancer diagnostics and product updates see Abbott Laboratories stock fall amid oversold technicals - Traders Union
Abbott Laboratories Bets on Devices in 2026 Call - TipRanks
Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool
Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool
Abbott Laboratories (ABT) Lowers Earnings Outlook Amid Acquisiti - GuruFocus
Abbott Laboratories (ABT) Shares Fall 6.0% -- What GF Score of 8 - GuruFocus
Is Abbott Laboratories (ABT) Now Offering Value After A 20% Share Price Slide? - simplywall.st
Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix - WSJ
Abbott stock tumbles on earnings. Nutrition business is struggling and merger costs biting. - MSN
Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance - Investor's Business Daily
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's
Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters
Abbott Laboratories (ABT) Reports Q1 2026 Earnings with Mixed Re - GuruFocus
Abbott Laboratories (ABT) Reports Q1 2026 Earnings, Adjusts Fore - GuruFocus
Abbott Laboratories (ABT) Faces Investor Concerns After Earnings Update - GuruFocus
Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings (ABT:NYSE) - Seeking Alpha
Abbott cuts profit forecast in wake of Exact Sciences deal - Modern Healthcare
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat - Yahoo Finance
Abbott Laboratories: This Dividend Growth King Has Rarely Been So Cheap (NYSE:ABT) - Seeking Alpha
Stocks making the biggest moves midday: Abbott Labs, AMD, Charles Schwab, On Semi & more - CNBC
Leerink reiterates Abbott Labs stock rating at Market Perform By Investing.com - Investing.com India
Abbott Laboratories Q1 2026 Earnings Call Summary - Yahoo Finance
Abbott Laboratories (ABT) Reports Q1 Earnings In-Line with Expec - GuruFocus
Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock CracksAbbott Laboratories (NYSE:ABT) - Benzinga
Abbott cuts earnings outlook to reflect Exact Sciences buyout - MSN
Abbott lowers earnings forecast after $21B Exact Sciences buy - MedTech Dive
Health Care ETFs take notice as Abbott Laboratories slides on earnings - Seeking Alpha
Abbott Labs Reports Strong Q1 but Lowers EPS Guidance for 2026 - GuruFocus
Abbott Laboratories (ABL.DE) Drops 4.7% on XETRA After Earnings - Meyka
Abbott defeats lawsuit alleging Similac contaminated by heavy metals - Reuters
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Abbott Laboratories (ABT) Forecasts Neutral FX Impact on Q2 Reve - GuruFocus
Abbott (ABT) Maintains Revenue Growth Outlook Amidst Adjustments - GuruFocus
Abbott Laboratories (NYSE:ABT) Hits New 12-Month LowShould You Sell? - MarketBeat
Abbott (ABT.US) 1Q Adjusted EPS Beats; Nutrition Business Remains Weak - AASTOCKS.com
Abbott (ABT) Q1 2026 Earnings Call Transcript - The Motley Fool
Abbott Laboratories Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales - WSJ
Abbott Laboratories Q1 Earnings Call Highlights - MarketBeat
Abbott cuts profit forecast in wake of cancer screening deal - Crain's Chicago Business
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Proactive financial news
Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com India
Abbott Laboratories (ABT) Lowers Earnings Outlook Despite Revenue Growth - GuruFocus
Abbott Earnings Beat Estimates. Why the Stock Is Slumping. - Barron's
Market movers: Hims & Hers, Abbott Laboratories, QVC… - Proactive financial news
Transcript: Abbott Laboratories Q1 2026 Earnings Conference CallAbbott Laboratories (NYSE:ABT) - Benzinga
Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat - marketscreener.com
Abbott Cuts Profit Forecast in Wake of Cancer Screening Deal - Bloomberg.com
Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey
Abbott cuts profit forecast in wake of cancer-screening deal - The Business Times
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
1.09%
자본화:
|
볼륨(24시간):